Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano (Nasdaq: BNGO) reported that 13 independent studies published in 2026 analyzed 730 samples using optical genome mapping (OGM) in reproductive health and prenatal genetics. Studies covered male infertility, assisted reproduction, recurrent pregnancy loss, prenatal diagnosis and spontaneous abortion, comparing OGM with standard cytogenetic and sequencing methods.
Across key studies, OGM detected structural variants missed by prior tests, found genetic causes in unexplained infertility and recurrent miscarriage, showed up to 99.03% concordance with standard prenatal diagnostics, and helped resolve previously inconclusive carrier-screening cases when combined with long-read sequencing.
Bionano (Nasdaq: BNGO) announced the full retirement and cancellation of all outstanding Senior Secured Convertible Debentures with an aggregate face value of $20 million, issued in May 2024. The company used cash on hand, now carries no secured debt, and has all liens and restrictive covenants removed, increasing financial and operational flexibility.
Bionano (Nasdaq: BNGO) reported a peer-reviewed T-cell acute lymphoblastic leukemia (T-ALL) study in Modern Pathology using optical genome mapping (OGM).
In 91 T-ALL cases, OGM detected abnormalities in 97.8% of samples versus 55% for karyotyping, delivered added genomic insights in ~70%, identified 45 gene fusions (24 known, 21 novel), and supported refined T-ALL subtype classification in a single workflow.
Bionano (Nasdaq: BNGO) reported Q1 2026 revenue of $6.7 million, up 4% year over year, with consumables revenue of $3.9 million, up 20%. Flow cell sales rose 17% to 8,178. Reported and adjusted gross margin were both 49%, versus 46% in Q1 2025.
Operating expenses fell 2% to $11.1 million, while adjusted operating expense increased 7% to $9.1 million. The company highlighted new CPT reimbursement developments for optical genome mapping and guided Q2 2026 revenue to $7.5–$7.8 million and full-year 2026 revenue to $30–$33 million.
Bionano Genomics (Nasdaq: BNGO) appointed Al Luderer, Ph.D., as interim president and chief executive officer, effective May 5, 2026. Dr. Luderer will continue as chairman; director Chris Twomey becomes Lead Independent Director. Erik Holmlin stays on as an advisor. The company anticipates a seamless transition while the Board conducts a search for a permanent CEO.
Dr. Luderer has served on Bionano’s board since November 2011 and as chairman since June 2024, with about three decades of biotechnology leadership experience.
Bionano (Nasdaq: BNGO) reported on May 5, 2026 that 28 publications described optical genome mapping (OGM) utility in rare disease in Q1 2026, a ~56% increase vs Q1 2025. The studies analyzed 78 samples (≈225% increase) and report OGM resolving previously unsolved cases, improving SV characterization, and complementing sequencing.
Bionano Genomics (NASDAQ: BNGO) will report first quarter 2026 financial results and host a conference call and live webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET.
Participants can register via links on the company's investors page; a replay will be archived on Bionano's investor relations website for at least 30 days. Company and investor-relations contacts are provided for follow-up.
Bionano (Nasdaq: BNGO) announced a multicenter study published April 2026 showing optical genome mapping (OGM) can outperform traditional cytogenetic methods in multiple myeloma (MM). The study analyzed 211 MM samples, found high concordance with karyotyping, FISH and NGS, and reported OGM identified additional pathogenic findings in ~30% of subjects.
OGM identified relevant abnormalities in 92% of cases previously called normal by karyotype and resolved 82% of samples that previously failed karyotype, and detected complex events (chromoanagenesis) in ~29% of samples.
Bionano Genomics (Nasdaq: BNGO) reported Q4 2025 revenue of $8.0M (down 3% YoY) and full‑year 2025 revenue of $28.5M (down 7% YoY). Gross margin improved to 46% FY and installed OGM base reached 387 systems. Company guided 2026 revenue to $30–33M and Q1 2026 to $6.5–6.7M.
Operating expenses were cut significantly, cash and equivalents were $29.6M, and CMS increased the 2026 CLFS payment determination by 47% for OGM hematologic code.
Bionano (NASDAQ: BNGO) reported that 12 optical genome mapping (OGM) studies were presented at the 2026 ACMG Annual Meeting (March 14–18), a two-fold increase versus 2025. Presentations included four oral talks and eight posters across cancer genomics and constitutional genetic disorders.
The presentations highlighted OGM's ability to detect structural variants missed by other methods; a Greenwood Genetic Center workshop and a Baylor Genetics commercial OGM service release were also noted.